BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro

T Gargett, CK Fraser, G Dotti, ES Yvon… - Journal of …, 2015 - journals.lww.com
Cancer immunotherapy has long been used in the treatment of metastatic melanoma, and
an anti-CTLA-4 monoclonal antibody treatment has recently been approved by the US Food
and Drug Administration. Targeted therapies such as small molecule kinase inhibitors
targeting deregulated mitogen-activated protein kinase (MAPK) signaling have markedly
improved melanoma control in up to 50% of metastatic disease patients and have likewise
been recently approved. Combination therapies for melanoma have been proposed as a …